List of Excipients in Branded Drug ZOVIRAX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ZOVIRAX	acyclovir	0187-0993	POLYETHYLENE GLYCOL
Bausch Health US LLC	ZOVIRAX	acyclovir	0187-0994	CETOSTEARYL ALCOHOL
Bausch Health US LLC	ZOVIRAX	acyclovir	0187-0994	MINERAL OIL
Bausch Health US LLC	ZOVIRAX	acyclovir	0187-0994	PETROLATUM

Zovirax Excipient Strategy and Commercial Opportunities for Acyclovir Products

Last updated: September 25, 2026

Zovirax is the GlaxoSmithKline brand for acyclovir, an antiviral used for herpes simplex virus and varicella-zoster virus infections. Its core patents and regulatory exclusivities have expired, leaving commercial value in differentiated formulations, pediatric delivery, tolerability, preservative systems, manufacturing efficiency, and market-specific regulatory execution. The strongest opportunities are in topical semisolids, oral liquids, improved adherence products, and private-label or regional generic platforms.

What is Zovirax and which dosage forms are commercially relevant?

Zovirax contains acyclovir, a guanosine analogue that inhibits viral DNA polymerase after intracellular activation. The product has been marketed in oral, topical, and intravenous forms, although availability varies by country and product authorization.

Dosage form	Typical strength	Primary excipient strategy	Commercial position
Oral tablet	200 mg, 400 mg, 800 mg	Diluent, binder, disintegrant, lubricant, film coat	Mature generic market
Oral capsule	200 mg	Gelatin shell, fill blend, lubricant	Limited differentiation
Oral suspension	200 mg/5 mL in some markets	Suspending agent, sweetener, flavor, preservative	Pediatric and swallowing-difficulty opportunity
Topical cream	5% acyclovir	Emulsion base, humectant, surfactant, emollient	Strongest excipient differentiation
Intravenous formulation	50 mg/mL concentrate or equivalent	Solubilizer, pH control, tonicity adjustment	Hospital and supply-chain opportunity
Ophthalmic or regional topical products	Market-dependent	Sterile vehicle and preservative system	Country-specific opportunity

The U.S. Zovirax label identifies acyclovir as the active ingredient in oral and topical products, while excipient composition differs by dosage form and product presentation (U.S. Food and Drug Administration [FDA], 2016; DailyMed, n.d.-a).

What excipients are used in Zovirax topical cream?

Zovirax cream uses a conventional semisolid system intended to disperse 5% acyclovir and support application to herpetic lesions. Public labeling identifies excipients including propylene glycol, mineral oil, cetostearyl alcohol, sodium lauryl sulfate, poloxamer 407, dimethicone, and water or related vehicle components, depending on the market-specific formulation (DailyMed, n.d.-b).

What does each topical excipient contribute?

Excipient class	Representative function	Strategic relevance
Propylene glycol	Humectant, solvent, penetration-supporting vehicle	Can cause irritation in sensitive users; replacement may improve tolerability
Mineral oil	Emollient and occlusive vehicle	Supports skin feel and barrier effects
Cetostearyl alcohol	Consistency agent and co-emulsifier	Controls spreadability and cream structure
Sodium lauryl sulfate	Surfactant and emulsifier	May increase irritation potential
Poloxamer 407	Surfactant and rheology modifier	Helps stabilize the dispersed system
Dimethicone	Skin protectant and sensory modifier	Can improve glide and reduce tack
Purified water	Continuous phase	Controls viscosity, microbial risk, and manufacturing cost

The main formulation weakness is that conventional surfactant and solvent choices may produce stinging, dryness, or poor cosmetic acceptance on already inflamed skin. A differentiated acyclovir cream can target lower irritation, faster drying, improved lesion coverage, or better patient acceptance without changing the active ingredient.

What topical excipient innovations could compete with Zovirax?

The most practical opportunities are:

1. Low-irritation solvent systems. Replace or reduce propylene glycol and sodium lauryl sulfate where solubility and release performance permit.
2. Silicone-enhanced creams. Use dimethicone or related silicone systems to improve spreadability, reduce tack, and limit water loss.
3. Lamellar emulsions. Build a skin-compatible multilayer structure that supports moisturization and controlled release.
4. Anhydrous or low-water systems. Reduce microbial risk and improve physical stability, although manufacturing and patient feel must be managed.
5. Fast-drying film-forming systems. Use polymeric film formers to reduce transfer to clothing and improve dose retention.
6. Preservative-minimized systems. Use airless packaging, low-water composition, or validated manufacturing controls to reduce preservative burden.
7. Barrier-supportive vehicles. Add compatible skin-conditioning components for patients who experience recurrent irritation.

Any new excipient must be assessed for local tolerability, acyclovir release, particle-size effects, preservative efficacy, stability, container compatibility, and regulatory acceptability. FDA topical-product guidance emphasizes product quality attributes such as viscosity, globule or particle characteristics, pH, microbial quality, and drug release (FDA, 2022).

What excipients are used in oral acyclovir tablets?

Oral acyclovir tablets generally use conventional solid-dose excipients. The composition varies by manufacturer and strength but commonly includes a diluent, binder, disintegrant, lubricant, glidant, and film-coating system.

Which tablet excipients create commercial differentiation?

The strongest commercial levers are not usually the active ingredient. They are manufacturing performance and patient usability.

Opportunity	Excipient approach	Business value
Smaller tablet	Higher-density filler and optimized granulation	Improves swallowing and reduces packaging volume
Faster disintegration	Superdisintegrant and porous granule structure	Supports rapid dissolution
Lower friability	Binder optimization and controlled compression	Reduces breakage and rejects
Better dose flexibility	Scoring and uniform tablet architecture	Supports pediatric and renal dosing
Improved swallowability	Film coating, low-friction surface, smaller geometry	Supports adherence
Direct compression	Engineered excipient platform	Reduces processing steps and cost
Moisture protection	Barrier film coat and high-performance blister	Improves shelf stability

Acyclovir has limited aqueous solubility, so tablet development must control wetting, disintegration, particle size, and dissolution. A formulation that disintegrates quickly may still fail to deliver acceptable dissolution if the active is poorly wetted or agglomerated.

Is there a meaningful orally disintegrating tablet opportunity?

An orally disintegrating acyclovir tablet could address patients with dysphagia, pediatric users, and patients who cannot access water. The principal technical barriers are the high dose relative to typical orally disintegrating tablet formats, taste masking, tablet friability, and mouthfeel.

Potential excipients include:

• Mannitol or isomalt for cooling mouthfeel.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Polymer or lipid taste-masking systems.
• Sweeteners and flavors compatible with acyclovir stability.
• Low-moisture packaging to protect mechanical strength.

The opportunity is more credible for lower-dose regimens or multiparticulate delivery than for an 800 mg unit dose. A pediatric granule, mini-tablet, or dispersible sachet may offer a better product profile than a large orally disintegrating tablet.

What excipients are important in oral acyclovir suspension?

An oral suspension can expand access for children and adults who cannot swallow tablets. The excipient system must maintain uniform dose delivery after shaking, prevent rapid sedimentation, avoid caking, and provide acceptable taste.

Which oral-liquid excipients matter most?

Formulation function	Candidate excipient types
Suspending vehicle	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose combinations
Wetting	Polysorbate or alternative nonionic surfactants
Sweetening	Sucrose, sorbitol, sucralose, or other market-appropriate systems
Flavor	Fruit flavors selected for bitterness suppression
Buffering	Citrate or phosphate systems, subject to stability review
Preservation	Preservatives compatible with pH and packaging
Density control	Polyols and structured vehicles to reduce sedimentation
Packaging	Unit-dose cups, oral syringes, or ready-to-use bottles

The commercial advantage is not simply liquid dosage form availability. It is dose accuracy, caregiver convenience, reduced shaking burden, and stable taste throughout shelf life. A ready-to-use suspension with an oral syringe can compete more effectively than a product requiring reconstitution.

What formulation patents protect Zovirax products?

The principal acyclovir compound and legacy Zovirax formulation patents are expired in major markets. Acyclovir was introduced decades ago, and the basic compound patent estate no longer blocks generic entry. The FDA Orange Book remains the controlling source for current U.S. listed patents by reference product and dosage form (FDA, n.d.-a).

IP category	Zovirax position	Current commercial implication
Acyclovir compound	Expired	No basic-molecule exclusivity barrier
Original oral formulations	Expired or no longer commercially blocking	Generic tablets and capsules are established
Legacy topical formulations	Expired	Cream competition is permitted
Method-of-use patents	Historical and generally expired	No broad Zovirax use exclusivity
Current generic formulation patents	Applicant-specific	May protect manufacturing or delivery improvements
Trade secrets	Potentially active	Process controls, scale-up, and excipient know-how can remain valuable

Patent risk can still arise from a newly developed delivery platform, novel topical composition, crystalline form, manufacturing process, or packaging configuration. A company seeking differentiated protection should pursue claims directed to measurable formulation characteristics, composition ranges, release profiles, or process parameters rather than relying on broad acyclovir claims.

When did Zovirax lose exclusivity and when can generic products launch?

Zovirax lost practical market exclusivity years ago. Generic acyclovir products are available in the United States and other major markets. The timing of a specific generic launch depends on dosage form, applicant approval, Paragraph IV activity, litigation, supply readiness, and local substitution rules.

What is the Paragraph IV status of Zovirax?

Paragraph IV certifications concern patents listed in the Orange Book. Because the foundational Zovirax patents are expired, current applicants generally do not face the same patent challenge structure associated with newer branded drugs. The relevant analysis is product-specific and must distinguish acyclovir tablets, capsules, suspension, cream, and injectable presentations.

A generic applicant can use:

• An abbreviated new drug application for a conventional acyclovir product.
• A 505(b)(2) application for a materially different formulation or delivery system.
• A full or hybrid national application outside the United States, depending on jurisdiction.

A differentiated topical system may require comparative clinical or dermatologic data if formulation changes affect safety, local tolerability, or clinical performance.

What is the FDA and Orange Book status of Zovirax?

Zovirax and acyclovir products have long-standing FDA regulatory histories. Current U.S. regulatory status differs by dosage form and marketing authorization holder. DailyMed records provide product-label information, while the Orange Book identifies approved drug products and any listed patent or exclusivity information (FDA, n.d.-a; DailyMed, n.d.-a).

The key regulatory points are:

• Acyclovir is an established active pharmaceutical ingredient.
• Generic oral and topical products are approved through abbreviated pathways.
• Product-specific inactive ingredients must be justified for safety and performance.
• Topical products require tight control of viscosity, homogeneity, microbial quality, and drug release.
• Oral liquids require dose uniformity, sedimentation control, preservative effectiveness, and container-closure compatibility.
• Injectable products face sterility, endotoxin, particulate, pH, and stability requirements.

How strong is the Zovirax patent estate?

The legacy Zovirax patent estate is weak as an exclusivity barrier because the core patents have expired. The commercial moat is based on brand recognition, physician familiarity, distribution, manufacturing scale, and regulatory history rather than active blocking patents.

What IP barriers remain for new acyclovir products?

The relevant barriers are narrower:

• Formulation patents covering a specific vehicle or release profile.
• Process patents covering particle engineering, granulation, or sterile manufacture.
• Trade secrets involving scale-up and physical stability.
• Trademark restrictions on the Zovirax name and branding.
• Regulatory data and quality requirements for new dosage forms.
• Supply constraints for specialized excipients or packaging components.

A new entrant should complete a freedom-to-operate review covering acyclovir polymorphs, particle-size control, excipient combinations, topical delivery systems, and manufacturing methods. Expired Zovirax patents do not eliminate risk from later third-party patents.

Which companies are challenging or competing with Zovirax?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Acyclovir is a small molecule, so biosimilar legislation and biologic interchangeability rules do not apply.

The competitive field includes:

• Generic tablet and capsule manufacturers.
• Generic topical cream manufacturers.
• Contract manufacturers offering private-label acyclovir.
• Valacyclovir manufacturers competing on oral dosing convenience.
• Famciclovir manufacturers competing in herpesvirus treatment.
• Regional firms selling pediatric liquids or extemporaneous-compounding products.

Valacyclovir is a direct commercial comparator because it is a prodrug of acyclovir with improved oral bioavailability and less frequent dosing in several indications. Acyclovir can compete through lower cost, established clinical use, and formulation-specific convenience.

What licensing and commercial opportunities exist for acyclovir excipients?

The best licensing targets are platform technologies that solve a defined product problem:

1. Topical delivery platforms that reduce irritation or improve lesion retention.
2. Taste-masking systems for pediatric oral liquids and dispersible products.
3. High-load granulation systems for smaller tablets.
4. Preservative-reduced oral suspensions with robust microbial control.
5. Airless or unit-dose packaging that improves stability and dosing accuracy.
6. Continuous manufacturing processes that reduce cost and variability.
7. Regional co-development deals for pediatric or hospital dosage forms.

A licensing package is commercially stronger when it includes comparative dissolution, skin permeation or release data, irritation testing, stability data, scale-up evidence, and a clear regulatory pathway.

What generic launch scenarios exist for Zovirax products?

Launch scenario	Product concept	Commercial risk	Upside
Low-cost oral generic	Standard tablet or capsule	High competition	Low
Premium topical generic	Lower-irritation cream	Moderate development cost	Moderate
Pediatric liquid	Ready-to-use suspension with syringe	Taste and stability risk	High in underserved segments
Dispersible product	Mini-tablet or sachet	Dose and taste complexity	Moderate to high
Hospital injectable	Reliable sterile supply	Manufacturing and quality burden	Moderate
Private-label dermatology product	Branded or retailer topical	Marketing dependence	Moderate

Revenue exposure for the legacy Zovirax brand is difficult to isolate because acyclovir sales are distributed across branded, generic, regional, and hospital channels. The largest opportunity is unlikely to come from replacing a protected brand. It is more likely to come from capturing a defined usability or supply-chain segment.

How does Zovirax compare with competing antiviral products?

Product	Active ingredient	Main differentiation	Excipient opportunity
Zovirax	Acyclovir	Established brand and broad historical use	Topical tolerability, pediatric delivery
Generic acyclovir	Acyclovir	Lowest-cost substitution	Manufacturing efficiency
Valtrex and generic valacyclovir	Valacyclovir	Improved oral exposure and dosing convenience	Smaller tablets, taste masking
Famvir and generic famciclovir	Famciclovir	Alternative oral antiviral regimen	Solid-dose convenience
Penciclovir topical products	Penciclovir	Alternative topical mechanism and regimen	Cream feel and lesion retention

Acyclovir products compete effectively where price, familiarity, and local availability matter. Valacyclovir has a stronger convenience proposition for selected oral regimens, while topical acyclovir requires superior tolerability or cosmetic performance to justify a differentiated position.

Key Takeaways

• Zovirax contains acyclovir and has no remaining core patent exclusivity in major markets.
• The strongest excipient opportunity is topical formulation improvement, particularly lower irritation, better spreadability, and stronger lesion retention.
• Pediatric oral suspensions, ready-to-use liquids, dispersible mini-tablets, and taste-masked products offer higher differentiation than standard tablets.
• Acyclovir is a small molecule, so biosimilar competition is irrelevant.
• Generic competition is established; commercial success depends on cost, usability, supply reliability, and regulatory execution.
• New patent value is most likely in formulation composition, process control, delivery systems, and packaging.
• Valacyclovir and famciclovir are the main oral antiviral comparators.
• Licensing opportunities are strongest for excipient platforms supported by stability, release, tolerability, and scale-up data.

FAQs

Can a new acyclovir cream obtain patent protection?

Yes. Patent protection may be available for a novel excipient composition, delivery system, release profile, process, or packaging configuration. Broad claims covering acyclovir alone are unlikely to provide meaningful protection because the active ingredient is long established.

Is propylene glycol essential in Zovirax cream?

No. It is a formulation component, not an irreplaceable requirement. A replacement system must maintain acyclovir uniformity, release, stability, skin tolerability, and manufacturability.

Is acyclovir suspension commercially attractive for pediatric use?

Yes, particularly where products provide accurate oral-syringe dosing, acceptable taste, minimal shaking, and reliable shelf stability. Pediatric usability is a more defensible differentiation strategy than another standard tablet.

Does a new acyclovir formulation require a 505(b)(2) application?

It may. The pathway depends on the extent of formulation change, whether the applicant can rely on an existing reference product, and whether additional clinical or comparative data are needed. A conventional equivalent may qualify for an ANDA instead.

Are Zovirax excipients identical across countries?

No. Inactive ingredients, product strengths, packaging, and authorized dosage forms can vary by jurisdiction. Regulatory and freedom-to-operate analysis must use the specific country and product presentation.

References

DailyMed. (n.d.-a). Zovirax: Acyclovir tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

DailyMed. (n.d.-b). Zovirax: Acyclovir cream prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (2016). Zovirax prescribing information. FDA.

U.S. Food and Drug Administration. (2022). Draft guidance for industry: Acyclovir topical cream, 5%. FDA.

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/񎟿